CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies
Author:
Affiliation:
1. Division of Hematology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain
2. Division of Oncology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain
Publisher
Impact Journals, LLC
Subject
Oncology
Reference20 articles.
1. Cdks, cyclins and CKIs: roles beyond cell cycle regulation;Kaldis;Development,2013
2. CDK9 inhibitors in cancer research;Fan;RSC Med Chem,2022
3. Targeting CDK9 for Anti-Cancer Therapeutics;Strebhardt;Cancers (Basel),2021
4. CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents;Albrecht;Front Oncol,2021
5. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma;Shortt;Leukemia,2015
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development;Bioorganic & Medicinal Chemistry Letters;2024-11
2. Single-molecule live imaging of subunit interactions and exchange within cellular regulatory complexes;2024-06-25
3. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications;Journal of Medicinal Chemistry;2024-04-02
4. CANCER THERAPY BY CYCLIN-DEPENDENT KINASE INHIBITORS (CDKIS): BENCH TO BEDSIDE;EXCLI J;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3